Anticancer drug utilizing Trans-splicing Ribozyme technology Second Fast Track Designation following brain cancer approval SEONGNAM, South Korea, Feb. 18, 2025 /PRNewswire/ — Rznomics announced on the 14th that its anticancer drug, RZ-001, has received Fast Track Designation from the U.S….
